WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H329993
CAS#: 50-14-6
Description: Ergocalciferol, also known as Vitamin D2 and calciferol, is a type of vitamin D found in food and used as a dietary supplement. As a supplement it is used to prevent and treat vitamin D deficiency. This includes vitamin D deficiency due to poor absorption by the intestines or liver disease. It may also be used for low blood calcium due to hypoparathyroidism. It is used by mouth or injection into a muscle.
Hodoodo Cat#: H329993
Name: Ergocalciferol
CAS#: 50-14-6
Chemical Formula: C28H44O
Exact Mass: 396.34
Molecular Weight: 396.659
Elemental Analysis: C, 84.79; H, 11.18; O, 4.03
Synonym: Ergocalciferol; Viosterol; Vitamin D2; calciferol,
IUPAC/Chemical Name: (S,Z)-3-(2-((1R,3aS,7aR,E)-1-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)-4-methylenecyclohexan-1-ol
InChi Key: MECHNRXZTMCUDQ-RKHKHRCZSA-N
InChi Code: InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1
SMILES Code: O[C@@H]1C/C(C(CC1)=C)=C/C=C2[C@]3([H])CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]3(C)CCC/2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Excessive doses can result in increased urine production, high blood pressure, kidney stones, kidney failure, weakness, and constipation. If high doses are taken for a long period of time, tissue calcification may occur. It is recommended that people on high doses have their blood calcium levels regularly checked. Normal doses are safe in pregnancy. It works by increasing the amount of calcium absorbed by the intestines and kidneys.[4] Food in which it is found include some mushrooms.
| Biological target: | Vitamin D2 (Ergocalciferol), drived from plant sources or dietary supplements, could be used as supplement of Vitamin D. |
| In vitro activity: | Exploration of the acting mechanisms involved this event revealed that ergocalciferol induced DNA fragmentation and increased sub-G1 DNA contents in HL-60 cells, both of which are hallmarks of apoptosis. Analysis of the integrity of mitochondria demonstrated that ergocalciferol caused loss of mitochondrial membrane potential with release cytochrome c to cytosol, generation of reactive oxygen species (ROS), and depletion of glutathione (GSH), suggesting that ergocalciferol may induce apoptosis in HL-60 cells through a ROS-dependent pathway. Reference: J Agric Food Chem. 2008 May 14;56(9):2996-3005. https://pubmed.ncbi.nlm.nih.gov/18386902/ |
| In vivo activity: | In the SNx group, ergocalciferol significantly increased overall contractile response to PE compared with vehicle (P < 0.0001) (Figure 3). The maximum achieved tension (g) was increased in the SNx group rats treated with ergocalciferol compared to SNx animals treated with vehicle whilst the potency remained unchanged (P = 0.03, Table 2). Reference: Biosci Rep. 2019 Dec 20; 39(12): BSR20190711. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923332/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 17.8 | 44.75 | |
| DMF | 20.0 | 50.42 | |
| Ethanol | 50.0 | 126.05 | |
| DMSO | 17.8 | 44.75 | |
| DMF | 20.0 | 50.42 | |
| Ethanol | 50.0 | 126.05 |
The following data is based on the product molecular weight 396.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Chen WJ, Huang YT, Wu ML, Huang TC, Ho CT, Pan MH. Induction of apoptosis by vitamin D2, ergocalciferol, via reactive oxygen species generation, glutathione depletion, and caspase activation in human leukemia Cells. J Agric Food Chem. 2008 May 14;56(9):2996-3005. doi: 10.1021/jf0730744. Epub 2008 Apr 3. PMID: 18386902. 2. Dreyer G, Kieswich J, Harwood S, Ahluwalia A, Yaqoob MM. Ergocalciferol improves endothelial vasodilatory and vasoconstrictor function in an in vivo model of mild uraemia. Biosci Rep. 2019 Dec 20;39(12):BSR20190711. doi: 10.1042/BSR20190711. PMID: 31789348; PMCID: PMC6923332. 3. Mitani H, Naru E, Yamashita M, Arakane K, Suzuki T, Imanari T. Ergocalciferol promotes in vivo differentiation of keratinocytes and reduces photodamage caused by ultraviolet irradiation in hairless mice. Photodermatol Photoimmunol Photomed. 2004 Oct;20(5):215-23. doi: 10.1111/j.1600-0781.2004.00116.x. PMID: 15379869. |
| In vitro protocol: | 1. Chen WJ, Huang YT, Wu ML, Huang TC, Ho CT, Pan MH. Induction of apoptosis by vitamin D2, ergocalciferol, via reactive oxygen species generation, glutathione depletion, and caspase activation in human leukemia Cells. J Agric Food Chem. 2008 May 14;56(9):2996-3005. doi: 10.1021/jf0730744. Epub 2008 Apr 3. PMID: 18386902. |
| In vivo protocol: | 1. Dreyer G, Kieswich J, Harwood S, Ahluwalia A, Yaqoob MM. Ergocalciferol improves endothelial vasodilatory and vasoconstrictor function in an in vivo model of mild uraemia. Biosci Rep. 2019 Dec 20;39(12):BSR20190711. doi: 10.1042/BSR20190711. PMID: 31789348; PMCID: PMC6923332. 2. Mitani H, Naru E, Yamashita M, Arakane K, Suzuki T, Imanari T. Ergocalciferol promotes in vivo differentiation of keratinocytes and reduces photodamage caused by ultraviolet irradiation in hairless mice. Photodermatol Photoimmunol Photomed. 2004 Oct;20(5):215-23. doi: 10.1111/j.1600-0781.2004.00116.x. PMID: 15379869. |
1: Shu G, Khalid N, Zhao Y, Neves MA, Kobayashi I, Nakajima M. Formulation and stability assessment of ergocalciferol loaded oil-in-water nanoemulsions: Insights of emulsifiers effect on stabilization mechanism. Food Res Int. 2016 Dec;90:320-327. doi: 10.1016/j.foodres.2016.10.021. Epub 2016 Oct 18. PubMed PMID: 29195888.
2: Dereje S, Muradov I, Nazzal S, Nguyen T. Cholecalciferol (D₃) Versus Ergocalciferol (D₂) in Older Adults. Consult Pharm. 2017 Jun 1;32(6):337-339. doi: 10.4140/TCP.n.2017.337. Review. PubMed PMID: 28595683.
3: Susantitaphong P, Nakwan S, Peerapornratana S, Tiranathanagul K, Katavetin P, Srisawat N, Praditpornsilpa K, Eiam-Ong S. A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria. BMC Nephrol. 2017 Jan 14;18(1):19. doi: 10.1186/s12882-017-0436-6. PubMed PMID: 28088187; PubMed Central PMCID: PMC5237567.
4: Wetmore JB, Kimber C, Mahnken JD, Stubbs JR. Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial. Br J Nutr. 2016 Dec;116(12):2074-2081. doi: 10.1017/S000711451600427X. Epub 2017 Jan 9. PubMed PMID: 28065190.
5: Hymøller L, Jensen SK. Plasma transport of ergocalciferol and cholecalciferol and their 25-hydroxylated metabolites in dairy cows. Domest Anim Endocrinol. 2017 Apr;59:44-52. doi: 10.1016/j.domaniend.2016.11.002. Epub 2016 Nov 16. PubMed PMID: 27940098.
6: Agarwal G, Hirachan P, Gelfond J, Fanti P, Hura C, Bansal S. Ergocalciferol treatment does Not improve erythropoietin utilization and hospitalization rate in hemodialysis patients. BMC Nephrol. 2016 Oct 7;17(1):144. PubMed PMID: 27717322; PubMed Central PMCID: PMC5055677.
7: Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology. 2016 Jul 12;87(2):239. doi: 10.1212/WNL.0000000000003021. PubMed PMID: 27402945.
8: Zhang D, Li H, Yin D, Wang L, Ma Y. Ergocalciferol versus calcitriol for controlling chronic kidney disease mineral bone disorder in stage 3 to 5 CKD: A randomized controlled trial. Eur J Pharmacol. 2016 Oct 15;789:127-133. doi: 10.1016/j.ejphar.2016.07.019. Epub 2016 Jul 9. PubMed PMID: 27401037.
9: Bauchner H, Redberg RF. Notice of Retraction: Sato Y, et al. The Prevention of Hip Fracture With Risedronate and Ergocalciferol Plus Calcium Supplementation in Elderly Women With Alzheimer Disease: A Randomized Controlled Trial. Arch Intern Med. 2005;165(15):1737-1742. JAMA Intern Med. 2016 Sep 1;176(9):1256. doi: 10.1001/jamainternmed.2016.3177. PubMed PMID: 27258431.
10: Miskulin DC, Majchrzak K, Tighiouart H, Muther RS, Kapoian T, Johnson DS, Weiner DE. Ergocalciferol Supplementation in Hemodialysis Patients With Vitamin D Deficiency: A Randomized Clinical Trial. J Am Soc Nephrol. 2016 Jun;27(6):1801-10. doi: 10.1681/ASN.2015040468. Epub 2015 Dec 17. PubMed PMID: 26677862; PubMed Central PMCID: PMC4884115.
11: Bunyaratavej N. Study of the Safe Dosage of Ergocalciferol. J Med Assoc Thai. 2015 Sep;98 Suppl 8:S13-5. PubMed PMID: 26529808.
12: Thimachai P, Supasyndh O, Chaiprasert A, Satirapoj B. Efficacy of High vs. Conventional Ergocalciferol Dose for Increasing 25-Hydroxyvitamin D and Suppressing Parathyroid Hormone Levels in Stage III-IV CKD with Vitamin D Deficiency/Insufficiency: A Randomized Controlled Trial. J Med Assoc Thai. 2015 Jul;98(7):643-8. PubMed PMID: 26267985.
13: Dickerson RN, Berry SC, Ziebarth JD, Swanson JM, Maish GO 3rd, Minard G, Brown RO. Dose-response effect of ergocalciferol therapy on serum 25-hydroxyvitamin D concentration during critical illness. Nutrition. 2015 Oct;31(10):1219-23. doi: 10.1016/j.nut.2015.03.008. Epub 2015 Apr 4. PubMed PMID: 26213135.
14: Mitchell DM, Leder BZ, Cagliero E, Mendoza N, Henao MP, Hayden DL, Finkelstein JS, Burnett-Bowie SA. Insulin secretion and sensitivity in healthy adults with low vitamin D are not affected by high-dose ergocalciferol administration: a randomized controlled trial. Am J Clin Nutr. 2015 Aug;102(2):385-92. doi: 10.3945/ajcn.115.111682. Epub 2015 Jul 8. PubMed PMID: 26156733; PubMed Central PMCID: PMC4515870.
15: Melhem SJ, Aiedeh KM, Hadidi KA. Effects of a 10-day course of a high dose calciferol versus a single mega dose of ergocalciferol in correcting vitamin D deficiency. Ann Saudi Med. 2015 Jan-Feb;35(1):13-8. doi: 10.5144/0256-4947.2015.13. PubMed PMID: 26142932.
16: Mangoo-Karim R, Da Silva Abreu J, Yanev GP, Perez NN, Stubbs JR, Wetmore JB. Ergocalciferol versus Cholecalciferol for Nutritional Vitamin D Replacement in CKD. Nephron. 2015;130(2):99-104. doi: 10.1159/000430813. Epub 2015 Jun 2. PubMed PMID: 26044704.
17: Agarwal G, Vasquez K, Penagaluru N, Gelfond J, Qunibi WY. Treatment of vitamin D deficiency/insufficiency with ergocalciferol is associated with reduced vascular access dysfunction in chronic hemodialysis patients. Hemodial Int. 2015 Oct;19(4):499-508. doi: 10.1111/hdi.12292. Epub 2015 Mar 19. PubMed PMID: 25790374.
18: Del Valle E, Negri AL, Fradinger E, Canalis M, Bevione P, Curcelegui M, Bravo M, Puddu M, Marini A, Ryba J, Peri P, Rosa Diez G, Sintado L, Gottlieb E. Weekly high-dose ergocalciferol to correct vitamin D deficiency/insufficiency in hemodialysis patients: a pilot trial. Hemodial Int. 2015 Jan;19(1):60-5. doi: 10.1111/hdi.12209. Epub 2014 Sep 17. PubMed PMID: 25231816.
19: Nguyen VT, Li X, Castellanos KJ, Fantuzzi G, Mazzone T, Braunschweig CA. The accuracy of vitamin D assays of circulating 25-hydroxyvitamin D values: influence of 25-hydroxylated ergocalciferol concentration. J AOAC Int. 2014 Jul-Aug;97(4):1048-55. PubMed PMID: 25145136.
20: Dreyer G, Tucker AT, Harwood SM, Pearse RM, Raftery MJ, Yaqoob MM. Ergocalciferol and microcirculatory function in chronic kidney disease and concomitant vitamin d deficiency: an exploratory, double blind, randomised controlled trial. PLoS One. 2014 Jul 9;9(7):e99461. doi: 10.1371/journal.pone.0099461. eCollection 2014. PubMed PMID: 25006678; PubMed Central PMCID: PMC4090117.
